October 2024. American scientist Laura Seeholzer, Ph.D., Postdoctoral Fellow at the University of California, San Francisco, USA, received the 2024 Eppendorf & Science Prize for Neurobiology for her work on elucidating a role for airway neuroendocrine cells in responding to external threats. Laryngeal and tracheal NE cells are critical, previously overlooked cell populations that protect our airways. Seeholzer aims to understand whether NE cell dysregulation contributes to an increased likelihood of aspiration as people age or in diseases where critical airway reflexes are compromised.
Two finalists were also recognized. Rosemary Cater, Ph.D., Senior Research Fellow & Group Leader at the University of Queensland, Brisbane, Australia, for her work that reveals molecular details of how the essential nutrients choline and omega-3 fatty acids are transported into the brain, and Claudia Kathe, Ph.D., Assistant Professor at the University of Lausanne, Switzerland, for her work on elucidating the role of neuronal populations in the spinal cord in restoring motor function.
The annual Eppendorf & Science Prize for Neurobiology is awarded jointly by Eppendorf and the journal Science. Researchers who are 35 years of age or younger and have made outstanding contributions to neurobiological research based on methods of molecular, cellular, systems, or organismic biology are invited to apply. The winner receives US$ 25,000 and has his or her essay published in Science. The next deadline for applications is June 15, 2025.
Source: Eppendorf SE
Disclaimer: You agree that B2Bioworld is not responsible and will not be held liable for any third party content on its sites or any third-party content, products or services available on other web sites accessed through links from B2Bioworld sites. Links to third-party sites are for your convenience only, and their inclusion on B2Bioworld\'s sites does not imply any endorsement, guarantee, warranty or representation by B2Bioworld.
B2Bioworld offers you background information
On voice-assistants, clinical trials, pathologies, and the COVID-19 bet. Includes interview with Guy Fagherazzi, Luxembourg Institute of Health